Oxford Biomedica rebrands as OXB amid business transformation
Oxford Biomedica has rebranded as OXB to reinforce the firm’s transformation into a global pure-play cell and gene therapy contract development and manufacturing organisation (CDMO).
The company says the new identity reflects its “unique combination of technical excellence, innovation and commitment to deliver consistent high quality at every stage of viral vector development and manufacturing”.
Dr Frank Mathias, CEO of OXB, said: “This rebranding is more than just a new look – it reflects the global nature of our operations and our deep commitment to the success of our clients’ drug development programmes.
“As OXB, with our new capabilities and global footprint, we’re ideally positioned to communicate our end-to-end services to current and potential clients and to interact with them from early-stage development through to commercial manufacturing.”
OXB had previously risen to prominence as manufacturer of the AstraZeneca Covid-19 vaccines.
